Skip to main content

Table 4 Reaction rates with rush mOIT

From: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Initial escalation day

Escalations performed

25

  Reactions

13 (52%)

  Mild (Grade 1)

13 (52%)

  Moderate (Grade 2)

0

  Severe (Grade 3)

0

Epinephrine use

0

Dose escalations

Doses administered

227

Reactions

13 (5.7%)

  Mild (Grade 1)

13 (5.7%)

  Moderate (Grade 2)

0

  Severe (Grade 3)

0

Median reaction rate [range]

0% [0–25]

Epinephrine use

0

Home dosing

Doses administered

7530

Reactions

401 (5.3%)

  Mild (Grade 1)

385 (5.1%)

  Moderate (Grade 2)

15 (0.2%)

  Severe (Grade 3)

1 (0.01%)

Median reaction rate [range]

3.2% [0.1-18.5]

Epinephrine use

1 (0.01%)